3 Biotechs With 50%+ Upside

Here are three "Strong Buy" Biotech stocks from Wall Street Here are three "Strong Buy" Biotech stocks from Wall Street                                                                                                      You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Dear Fellow Investor, Biotech stocks have been a hot topic in the investment world for several years now. With advancements in technology and an increased focus on healthcare, the biotech industry has experienced significant growth and innovation. As a result, many investors are turning to biotech stocks as a way to diversify their portfolio and potentially earn significant returns. Here are three "Strong Buy" Biotech stocks from Wall Street - NewAmsterdam Pharma Company N.V. – SYM: NAMS Recent Price: $9.80 Price Target: $25.00 Firms with Buy Rating: Jefferies, RBC Capital, Credit Suisse Description: NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). === [Your new "Quick Response" bank account]( [qr code](The Federal government could soon mail you a private QR code. It'll be your passport to a new financial system... as important as your bank account or social security number. It's the biggest change to money in America in decades... [And it's crucial you understand how it'll impact you ASAP.]( === Legend Biotech Corporation – SYM: LEGN Recent Price: $59.98 [Get Price Target Here ]( Firms with Buy Rating: Citi, Jefferies, Goldman Sachs Description: Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. === [Could This New A.I. Stock Breakthrough Give Main Street the Edge?]( [lightbulb]( TradeSmith is on a mission to take the power of A.I.-driven investing AWAY from the Wall Street elites… And into in the hands of everyday folks like YOU. Today, they’re unveiling a breakthrough, new report to give you the roadmap: How A.I. Investing Can Improve Your Portfolio. At the heart of this is a A.I. stock forecasting algorithm called An-E (pronounced Annie, short for Analytical Engine) that could predict stock prices one month into the future with remarkable accuracy. [CLICK HERE to access your free report now!]( By clicking the link above, you'll also be opted into TradeSmith Daily free newsletter. You may unsubscribe at any time. === Sarepta Therapeutics, Inc. – SYM: SRPT Recent Price: $83.44 [Get Price Target Here ]( Firms with Buy Rating: J.P. Morgan, Barclays, Needham Description: Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. === [3 Top NASDAQ Stocks to Buy for 2024](The tech-heavy NASDAQ is having an explosive year. In fact, since the year began, the index is up about 32%, which could easily carry well into New Year 2024. All thanks to the artificial intelligence boom that shows no signs of slowing. Helping, Big Tech has been investing billions into AI, which isn't slowing either. That being said, investors may want to strongly consider picking up these red-hot stocks. All of which could push the NASDAQ to higher highs. [Click Here to Sign up for our FREE Report and subscription to InvestingDistrict]( By clicking this link you agree to receive emails from Investing District and StockMarketVibes === [Daily Guru Trades]( Want more free daily trades in your inbox? Sign up for Dylan Jovine's Daily Guru Trades [Here.]( "The Buck Stops Here" [youtube button]( [facebook button]( [instagram button]( Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2023 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe](